Table 3 Current clinical trials using scaffolds delivering MSCs for diabetic foot ulcer (from clinicaltrials.gov, 7th January 2022)
From: Scaffold-based delivery of mesenchymal stromal cells to diabetic wounds
Identifier | Trial name | Study phase | Cell type | Cell delivery method | Recruitment status | Sponsor | Location |
|---|---|---|---|---|---|---|---|
NCT02394886 | Safety of ALLO-ASC-DFU in the patients with diabetic foot ulcers | Phase 1 | Allogeneic AD-MSCs | Hydrogel scaffold | Completed | Anterogen Co., Ltd | Korea |
NCT02619877 | Clinical study to evaluate efficacy and safety of ALLO-ASC-DFU in patients with diabetic foot ulcers | Phase 2 | Allogeneic AD-MSCs | Hydrogel scaffold | Completed | Anterogen Co., Ltd | Korea |
NCT03183726 | A follow-up study to evaluate the safety of ALLO-ASC-DFU in ALLO-ASC-DFU-101 clinical trial | Phase 1 | Allogeneic AD-MSCs | Hydrogel scaffold | Completed | Anterogen Co., Ltd | Korea |
NCT03183804 | A follow-up study to evaluate the safety of ALLO-ASC-DFU in ALLO-ASC-DFU-201 clinical trial | Phase 2 | Allogeneic AD-MSCs | Hydrogel scaffold | Unknown | Anterogen Co., Ltd | Korea |
NCT03370874 | Clinical study to evaluate efficacy and safety of ALLO-SC-DFU in patients with diabetic foot ulcers | Phase 3 | Allogeneic AD-MSCs | Hydrogel scaffold | Active, not recruiting | Anterogen Co., Ltd | Korea |
NCT03754465 | Clinical study of ALLO-ASC-SHEET in subjects with diabetic foot ulcers | Phase 2 | Allogeneic AD-MSCs | Hydrogel scaffold | Recruiting | Anterogen Co., Ltd | United states |
NCT04497805 | Clinical study of ALLO-ASC-SHEET in subjects with diabetic wagner grade II foot ulcers | Phase 2 | Allogeneic AD-MSCs | Hydrogel scaffold | Recruiting | Anterogen Co., Ltd | United states |
NCT04569409 | Clinical study to evaluate efficacy and safety of ALLO-ASC-DFU in patients with diabetic wagner grade 2 foot ulcers | Phase 3 | Allogeneic AD-MSCs | Hydrogel scaffold | Recruiting | Anterogen Co., Ltd | Korea |
NCT04464213 | Human placental Mesenchymal stem cell treatment on diabetic foot ulcer | Phase 1 | Placental MSCs | Hydrogel scaffold | Recruiting | Beijing Tongren Hospital | China |
NCT03865394 | Treatment of chronic wounds in diabetic foot syndrome with autologous adipose derived mesenchymal stem cells (1ABC) | Phase 1 Phase 2 | Autologous AD-MSCs | Hydrogel scaffold | Completed | Medical University of Warsaw | Poland |
NCT03248466 | PRG combined with autologous BMMSCs for treatment of diabetic foot ulcer | Early phase 1 | Autologous BM-MSCs | Hydrogel scaffold | Unknown | Third Military Medical University | China |
NCT03259217 | Clinical application of mesenchymal stem cells seeded in chitosan scaffold for diabetic foot ulcers | Phase 1 | AD-MSCs | Sponge scaffold | Unknown | Assiut University | Korea |
NCT02672280 | Safety and exploratory efficacy study of collagen membrane with mesenchymal stem cells in the treatment of skin defects | Phase 1 Phase 2 | UC-MSCs | Sponge scaffold | Unknown | South China Research Centre for Stem Cell and Regenerative Medicine | China |